{"protocolSection":{"identificationModule":{"nctId":"NCT05169450","orgStudyIdInfo":{"id":"TJ2013012"},"organization":{"fullName":"Dongzhimen Hospital, Beijing","class":"OTHER"},"briefTitle":"Efficacy of Diterpene Ginkgolides Meglumine Injection in Elderly Patients With Ischemic Stroke","officialTitle":"Efficacy of Diterpene Ginkgolides Meglumine Injection in Elderly Patients With Ischemic Stroke: A Post Hoc Analysis of a Randomized Controlled Trial"},"statusModule":{"statusVerifiedDate":"2021-12","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2013-07-01","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2014-04-01","type":"ACTUAL"},"completionDateStruct":{"date":"2014-04-01","type":"ACTUAL"},"studyFirstSubmitDate":"2021-12-06","studyFirstSubmitQcDate":"2021-12-23","studyFirstPostDateStruct":{"date":"2021-12-27","type":"ACTUAL"},"lastUpdateSubmitDate":"2021-12-23","lastUpdatePostDateStruct":{"date":"2021-12-27","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"PRINCIPAL_INVESTIGATOR","investigatorFullName":"Ying Gao","investigatorTitle":"Professor","investigatorAffiliation":"Dongzhimen Hospital, Beijing"},"leadSponsor":{"name":"Dongzhimen Hospital, Beijing","class":"OTHER"}},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false,"isUsExport":false},"descriptionModule":{"briefSummary":"A randomized positived-controlled study of Diterpene Ginkgolides Meglumine Injection (DGMI) vs Ginaton in patients with ischemic stroke (IS) was conducted between7/2013 and 4/2014. The study was designed to test efficacy of DGMI for IS. Post hoc analysis of this trial was conducted to evaluate the efficacy of DGMI in elderly (aged≥65 years) IS patients.","detailedDescription":"To examine the efficacy of Diterpene Ginkgolides Meglumine Injection (DGMI) vs Ginaton in patients with ischemic stroke (IS) by age subgroups. The efficacy analysis was a post hoc analysis of data from a large randomized, controlled study was performed in a cohort of 998 IS patients. Patients were pooled and grouped by age (elderly aged ≥ 65 years and non-elderly aged \\< 65 years).Proportion of patients with Modified Rankin Scale (mRS) less than or equal to 1 at 90days is the primary outcome measure."},"conditionsModule":{"conditions":["Stroke","Ischemic Stroke","Nervous System Diseases","Cerebral Infarction","Brain Ischemia","Brain Infarction"],"keywords":["Diterpene Ginkgolides Meglumine Injection","acute ischemic stroke","effectiveness"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["NA"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":998,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Diterpene ginkgolides meglumine injection","type":"EXPERIMENTAL","description":"The intervention group received daily single infusions of 25 mg diterpene ginkgolides meglumine injection (DGMI) diluted with 250 ml of 0.9% sodium chloride injection for 14 days.","interventionNames":["Drug: Diterpene ginkgolides meglumine injection"]},{"label":"Ginaton","type":"ACTIVE_COMPARATOR","description":"The control group received once or twice a day infusion of 35-60mg Ginaton diluted with 250 ml of 0.9% sodium chloride injection for 14 days.","interventionNames":["Drug: Ginaton"]}],"interventions":[{"type":"DRUG","name":"Diterpene ginkgolides meglumine injection","description":"Patients will receive intravenously administered diterpene ginkgolides meglumine injection, combined with guidelines-based standard care.","armGroupLabels":["Diterpene ginkgolides meglumine injection"],"otherNames":["Ginkgolides Diterpene Lactone Meglumine Injection"]},{"type":"DRUG","name":"Ginaton","description":"Patients will receive intravenously administered Ginaton, combined with guidelines-based standard care.","armGroupLabels":["Ginaton"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Excellent functional outcome","description":"Excellent functional outcome defined as an Modified Rankin Scale (mRS) score ≤ 1 at 90 days(scores ranged from 0 to 6, with 0 to 1 indicating no disability, 2 to 5 indicating increasing disability, and 6 indicating death)","timeFrame":"90 days"}],"secondaryOutcomes":[{"measure":"Neurological deficit amelioration","description":"neurological deficit amelioration, which was defined as a change in the National Institutes of Health Stroke Scale (NIHSS) score (range = 0-42, with higher scores indicating more severe strokes) from baseline to D14","timeFrame":"14 post-randomization days, 90days"},{"measure":"Patient quality of life","description":"Patient quality of life, as measured using the EuroQol questionnaire \\[consisting of two parts: EuroQol-5 Dimension(EQ-5D) and EQ visual analog scale (EQ-VAS)\\]. A value of 100 on this scale indicates a perfect score for health, whereas a score of 0 indicates death. The EQ-5D index score is measured on a scale of 0 (death) to 1 (full health).","timeFrame":"14 post-randomization days, 90days"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* 35 years of age or older, and gender not limited;\n* Between 2 and 4 weeks onset of ischemic stroke;\n* The first onset, or always not obvious legacy of stroke sequela (mRS acuities were before the onset of 1);\n* Understand and voluntarily signed informed consent.\n\nExclusion Criteria:\n\n* Known severe liver or kidney dysfunction;\n* Known allergies for ingredients in the investigational product;\n* Known medical condition likely to limit survival to less than 3 months;\n* Known dementia, mental impairment, or unsuitability for participation as judged by the investigators;\n* Hemorrhage transformation after infarction, or bleeding tendency;\n* Pregnancy or breastfeeding;\n* Known lower extremity venous thrombosis;\n* Having participated in others clinical trial within 1 month before randomization.","healthyVolunteers":false,"sex":"ALL","minimumAge":"35 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"locations":[{"facility":"Dongzhimen Hospital, Beijing University of Chinese Medicine","city":"Beijing","zip":"100700","country":"China","geoPoint":{"lat":39.9075,"lon":116.39723}}]},"referencesModule":{"seeAlsoLinks":[{"label":"Resource links provided by the National Library of Medicine","url":"https://druginfo.nlm.nih.gov/drugportal/name/Meglumine"},{"label":"Resource links provided by the National Library of Medicine","url":"https://druginfo.nlm.nih.gov/drugportal/name/Ginkgo+biloba"}]},"ipdSharingStatementModule":{"ipdSharing":"NO"}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000020521","term":"Stroke"},{"id":"D000083242","term":"Ischemic Stroke"},{"id":"D000002544","term":"Cerebral Infarction"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000002545","term":"Brain Ischemia"},{"id":"D000020520","term":"Brain Infarction"},{"id":"D000007511","term":"Ischemia"},{"id":"D000007238","term":"Infarction"}],"ancestors":[{"id":"D000002561","term":"Cerebrovascular Disorders"},{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"},{"id":"D000010335","term":"Pathologic Processes"},{"id":"D000009336","term":"Necrosis"}],"browseLeaves":[{"id":"M21996","name":"Stroke","asFound":"Stroke","relevance":"HIGH"},{"id":"M10233","name":"Ischemia","asFound":"Ischemic","relevance":"HIGH"},{"id":"M2401","name":"Ischemic Stroke","asFound":"Ischemic Stroke","relevance":"HIGH"},{"id":"M9972","name":"Infarction","asFound":"Infarction","relevance":"HIGH"},{"id":"M5483","name":"Cerebral Infarction","asFound":"Cerebral Infarction","relevance":"HIGH"},{"id":"M5484","name":"Brain Ischemia","asFound":"Brain Ischemia","relevance":"HIGH"},{"id":"M21995","name":"Brain Infarction","asFound":"Brain Infarction","relevance":"HIGH"},{"id":"M5500","name":"Cerebrovascular Disorders","relevance":"LOW"},{"id":"M4894","name":"Brain Diseases","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"},{"id":"M11974","name":"Necrosis","relevance":"LOW"},{"id":"T170","name":"Acute Graft Versus Host Disease","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"},{"abbrev":"Rare","name":"Rare Diseases"}]}},"hasResults":false}